Investigating Efficacy and Safety of JETi® in Arterial Occlusions in FEM-POP and Prox BTK-Lesions (JETART)

Launched by VASCULAR SCIENCE LP GMBH · May 23, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient is ≥18 years
• • Patient has Rutherford Classification 2,3 or 4.
• • Patient has provided written informed consent and is willing to comply with study follow-up requirements.
• • Angiographic inclusion criteria
• • De novo thrombotic occlusive lesion(s) or thrombotic re-occlusion or in-stent thrombotic occlusive lesion(s) or thrombotic occlusion of a bypass (autolog or prosthetic) occurring acute or subacute with onset of complains within \<30 days prior to first seen by investigating physician.
• • Target lesion is located between the ostium of the SFA and the end of the P3 segment of the popliteal artery, tibioperoneal trunk, respectively the first 10 cm of the below the knee vessels
• • Target vessel diameter ≥ 3 mm and ≤ 8 mm and irrespective of lesion length
• • Target lesion must be occlusive lesion Note: there is no limitation in lesion length
• • Successful, uncomplicated crossing of the target lesion occurs when the tip of the guidewire is distal to the target lesion without the occurrence of flow-limiting dissection of perforation and is judged by visual inspection to be within the true lumen.
• • A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography.
• • At least one patent native distal outflow artery to the ankle or foot, free from significant stenosis (≥ 50 % stenosis) as confirmed by angiography.
• Exclusion Criteria:
• • Patients meets any contraindication for JETi mechanical thrombectomy use per IFU
• • Lesion crossing is difficult and the lesion is not suspicious for fresh thrombus containment
• • Pregnant women or female patients of childbearing potential that do not use adequate contraceptive methods
• • Patient has a life expectancy of less than 1 year
• • Patient has a known allergy to contrast medium that cannot be adequately pre-medicated.
• • Patient is allergic to all anti-platelet treatments
• • Patient has platelet count \<100.000/mm3 or \>700.000/mm
• • Patient has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure
• • Patient is diagnosed with coagulopathy that bares the risk of increased bleeding risk
• • Patient has history of stroke within past 90 days
• • Patient is participating in an investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study.
• • Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure
• • Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol
• • Patient suffering from HIT II
• Angiographic Exclusion Criteria:
• • Target lesion is larger than 8 mm, respectively smaller than 3 mm
• • Significant target vessel tortuosity or other parameters prohibiting access to the target lesion
• • Absence of thrombus in the target vessel
• • Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤ 30 % residual diameter stenosis without death or major complications.
• • No patent outflow vessels on the level of 10 cm below the origin of below the-knee arteries to the level of the foot or ankle.